Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 in Combination With Etoposide and Cisplatin for Advanced Neuroendocrine Carcinoma
NCT07833839Phase 3Not yet recruiting
- Sponsor
- Zelgen
- Start
- Oct 2026
- Primary completion
- Oct 2031
- Countries
- 1
01
Overview
A Phase 3 trial of nilvanstomig in neuroendocrine carcinoma (NEC), sponsored by Zelgen. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
nilvanstomig
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07833839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07833839.